Clec4a Antibody

What is Clec4a and what are its key structural features?

Clec4a (CD367/DCIR) is a type II transmembrane protein belonging to the C-type lectin domain family. Its structure includes one carbohydrate recognition domain (CRD) in the C-terminal extracellular domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. The protein contains an N-glycosylation site within the CRD that is essential for its inhibitory function. This structural arrangement enables Clec4a to function as a negative regulator of immune responses through ITIM-mediated inhibitory signaling that requires homotypic interaction through binding of the EPS motif with the N-glycan .

What cell types express Clec4a?

Clec4a expression varies between species. In humans, CLEC4A is mainly expressed on monocytes, macrophages, dendritic cells, neutrophils, and B cells. It has also been detected on the surface of CD4+ T cells in rheumatoid arthritis patients . In mice, the expression pattern differs between variants - mClec4A4 is exclusively expressed on conventional dendritic cells (cDCs), particularly on CD8α- cDCs, while Clec4a2 is more broadly expressed in B cells, monocytes, macrophages, and dendritic cells .

How do Clec4a variants differ between mouse and human?

While several Clec4a family members exist, key functional relationships have been established between species. Murine Clec4A4 (mClec4A4) is considered the functional orthologue of human CLEC4A (hCLEC4A). Both share similar molecular mechanisms, with hCLEC4A exhibiting an ITIM-mediated suppressive function comparable to mClec4A4. This functional similarity has important implications for translational research, as findings in mouse models may have relevance to human applications. Researchers have created hCLEC4A-transgenic mice to better study the human protein's functions in vivo .

What experimental methods are commonly used to detect Clec4a expression?

Researchers typically use several complementary approaches to detect Clec4a expression:

• Flow cytometry with specific antibodies (such as the PE anti-human CD367 clone 9E8)

• Real-time PCR for mRNA expression analysis

• Immunohistochemistry for tissue-level expression studies

• Western blotting for protein expression detection

For flow cytometric applications, manufacturers recommend using approximately 5 μl of antibody per million cells in 100 μl staining volume or 5 μl per 100 μl of whole blood . When planning expression studies, researchers should consider that Clec4a expression can be correlated with other markers including CD163, Csf1r, Cd200r1, Clec7a, Tlr7, Scarb1, Cd68, Msr1, Mrc1, and Ms4a4a, particularly in tissue-resident and alternatively activated macrophages .

How does the ITIM domain of Clec4a mediate its inhibitory functions?

The ITIM domain in Clec4a's cytoplasmic region mediates inhibitory functions by recruiting Src homology region 2 domain-containing protein tyrosine phosphatase 1 (SHP1) and SHP2. These phosphatases downmodulate tyrosine phosphorylation signaling, resulting in reduced activation of dendritic cells and other immune cells. This mechanism is essential for Clec4a's role as a negative immune checkpoint regulator. The inhibitory effect requires the N-glycosylation site within the carbohydrate-recognition domains and is dependent on the ITIM motif for suppressive effects on dendritic cell activation, particularly cDC2 . This understanding provides opportunities for targeted interventions that could potentially block this inhibitory pathway.

How can researchers effectively target Clec4a in cancer immunotherapy studies?

When targeting Clec4a in cancer immunotherapy studies, several approaches have shown promise:

• Antagonistic antibodies: Developing antagonistic monoclonal antibodies to hCLEC4A has demonstrated protection against established tumors without apparent immune-related adverse events in hCLEC4A-transgenic mice. These antibodies block the inhibitory functions of Clec4a, enhancing antitumor immune responses .

• RNA interference: Skin delivery of Clec4a-specific small hairpin RNA (shRNA) using a gene gun has successfully delayed tumor growth in both bladder and lung tumor-bearing mouse models. This approach downregulates Clec4a expression, enhancing immune responses against tumors .

• Combination therapies: Researchers should consider combining Clec4a targeting with other immune checkpoint inhibitors or conventional cancer therapies for enhanced efficacy.

When designing such studies, it's critical to validate the specificity of targeting strategies and carefully monitor for potential immune-related adverse events, though initial studies suggest Clec4a blockade may have fewer side effects than some existing immune checkpoint inhibitors .

What methodologies are most effective for studying Clec4a's role in the tumor microenvironment?

To effectively study Clec4a's role in the tumor microenvironment (TME), researchers should employ multiple complementary methodologies:

• Genetic knockout models: Studies using Clec4a4-/- mice have shown reduced tumor development accompanied by enhanced antitumor immune responses and amelioration of the immunosuppressive TME through enforced activation of cDCs in tumor-bearing mice .

• Antibody-mediated inhibition: Antagonistic monoclonal antibodies can be used to block Clec4a function in vivo, allowing temporal control of inhibition compared to genetic knockouts .

• Ex vivo analysis of tumor-infiltrating immune cells: Immunohistochemistry and flow cytometry of tumor tissues can reveal changes in immune cell populations, particularly infiltrating CD4+ and CD8+ T cells. This approach has demonstrated increased tumor-infiltrating lymphocytes following Clec4a inhibition .

• Cytokine profiling: Real-time PCR and flow cytometry can be used to measure changes in cytokine production. For example, mRNA levels of IFN-γ were dramatically upregulated while IL-4 levels decreased in the spleens of mice treated with shClec4a .

These methodologies collectively provide insights into how Clec4a inhibition affects the immunosuppressive TME and enhances antitumor immune responses.

How do Clec4a knockout models differ from antibody-mediated inhibition in research studies?

Clec4a knockout models and antibody-mediated inhibition represent complementary but distinct research approaches:

Knockout Models:

• Provide complete absence of the target protein throughout development

• Allow investigation of developmental and long-term effects

• Eliminate concerns about antibody specificity and penetration

• Studies with Clec4a4-/- mice demonstrated reduced tumor development with enhanced antitumor immune responses

Antibody-Mediated Inhibition:

• Offers temporal control over inhibition

• Allows titration of inhibitory effect

• Better mimics potential therapeutic applications

• Antagonistic monoclonal antibodies to hCLEC4A have shown protection against established tumors

• Can be delivered to specific locations (e.g., skin delivery using a gene gun)

For comprehensive studies, researchers often benefit from using both approaches. The specific antibody-based approaches have included antagonistic monoclonal antibodies and gene gun delivery of shRNA, with the latter showing silencing efficacy that correlates directly with antitumor effects .

What experimental design considerations are important when using anti-Clec4a antibodies for in vivo studies?

When designing in vivo studies with anti-Clec4a antibodies, researchers should consider:

These considerations help ensure robust experimental results that can effectively elucidate Clec4a's role in immune regulation and its potential as a therapeutic target.

How does Clec4a contribute to the immunosuppressive tumor microenvironment?

Clec4a contributes to the immunosuppressive tumor microenvironment (TME) through several mechanisms:

• Negative regulation of dendritic cell activation: As an ITIM-containing receptor, Clec4a inhibits the activation of conventional dendritic cells (cDCs), particularly cDC2, limiting their ability to stimulate antitumor T cell responses .

• Cytokine modulation: Clec4a expression affects the balance of Th1 and Th2 cytokines. Inhibition of Clec4a shifts the balance toward Th1 responses, with increased IFN-γ and decreased IL-4 expression, creating a more favorable environment for antitumor immunity .

• Impact on tumor-infiltrating lymphocytes: Clec4a inhibition increases the number of tumor-infiltrating CD4+ and CD8+ T lymphocytes, suggesting that its normal function may limit T cell infiltration into tumors .

• Maintenance of immunosuppressive myeloid cells: Clec4a may contribute to the development or maintenance of immunosuppressive myeloid cell populations within the TME.

Studies demonstrate that genetic deletion or inhibition of Clec4a leads to amelioration of the immunosuppressive TME, highlighting its importance in maintaining an environment favorable for tumor growth .

What techniques can be used to study the interaction between Clec4a and its ligands?

Researchers have several options for studying Clec4a-ligand interactions:

• Surface plasmon resonance (SPR): This technique can measure binding kinetics and affinity between purified Clec4a and potential ligands.

• Pull-down assays and co-immunoprecipitation: These can identify protein-protein interactions and associated signaling complexes, particularly important for studying interactions with SHP-1 and SHP-2 phosphatases through the ITIM domain .

• Glycan array screening: Since Clec4a contains a carbohydrate recognition domain, glycan arrays can help identify specific carbohydrate structures recognized by the receptor.

• FRET-based interaction assays: These can detect molecular proximity between Clec4a and potential binding partners in living cells.

• Homotypic interaction studies: Research has shown that Clec4a's function requires homotypic interaction through binding of the EPS motif with N-glycan, suggesting this as an important aspect to investigate .

Understanding these interactions is crucial for developing targeted therapies, as the EPS motif binding with N-glycan appears to be a key mechanism for Clec4a's inhibitory function.

How can researchers distinguish between the effects of Clec4a on different dendritic cell subsets?

Distinguishing the effects of Clec4a on different dendritic cell (DC) subsets requires careful experimental design:

• Subset-specific markers: Use flow cytometry with markers that distinguish conventional DC (cDC) subsets. In mice, Clec4a4 is specifically expressed on CD8α- cDCs (cDC2), while Clec4a2 has broader expression patterns .

• Single-cell analysis: Techniques like single-cell RNA sequencing can reveal heterogeneity in Clec4a expression and function across DC populations.

• Subset depletion or sorting: Depleting or sorting specific DC subsets before experimental manipulation can isolate their contribution to observed effects.

• Conditional knockout models: Creating DC subset-specific Clec4a knockout models using promoters active only in certain DC populations would allow for precise attribution of effects.

• In vitro culture of specific DC subsets: Culturing sorted DC subsets with or without Clec4a inhibition/stimulation can directly assess functional differences.

Research has shown that Clec4a4 specifically regulates cDC2 activation, and knockdown studies demonstrate distinct effects on different DC subsets, underscoring the importance of subset-specific analysis .

What is the potential of Clec4a as a target for immune checkpoint blockade therapy?

Clec4a shows significant promise as a target for immune checkpoint blockade therapy for several reasons:

• Proven antitumor effects: Both genetic knockouts of mClec4A4 and antagonistic antibodies against hCLEC4A have demonstrated protection against established tumors in multiple mouse models .

• Favorable safety profile: Unlike some existing immune checkpoint inhibitors that can cause significant immune-related adverse events (irAEs), hCLEC4A targeting has not shown apparent signs of irAEs in preclinical models .

• Complementary mechanism to existing therapies: Clec4a focuses on enhancing dendritic cell function rather than directly targeting T cells, potentially offering synergistic effects when combined with existing T cell-focused checkpoint inhibitors.

• Translational relevance: The functional orthologue relationship between murine Clec4A4 and human CLEC4A suggests findings in mouse models may translate well to human applications .

Research indicates that targeting this pathway could lead to reduced tumor development, enhanced antitumor immune responses, and amelioration of the immunosuppressive tumor microenvironment through enforced activation of conventional dendritic cells .

How does Clec4a's role in HIV infection relate to its immunomodulatory functions?

Clec4a has been identified as a receptor for HIV, which connects to its broader immunomodulatory functions in several ways:

• Viral recognition and binding: As a C-type lectin receptor, Clec4a can recognize and bind to glycosylated viral proteins, serving as an attachment factor for HIV .

• Antigen presentation pathway: Clec4a's ability to internalize bound antigens allows it to deliver viral components into the antigen presentation pathway. This function enables Clec4a to cross-present and cross-prime human CD8+ T cells, which is relevant for both HIV immunity and tumor immunity .

• Inhibitory signaling: The inhibitory signaling mediated by Clec4a's ITIM domain may be exploited by HIV to suppress effective immune responses against the virus, similar to how it appears to suppress antitumor immunity .

This dual role as both a viral receptor and an immune inhibitory molecule makes Clec4a an interesting target for studying how pathogens exploit immune regulatory pathways. Understanding this relationship could potentially inform new approaches to both HIV treatment and cancer immunotherapy.

What are the best experimental approaches for investigating Clec4a's role in autoimmune diseases?

Given the associations between Clec4a polymorphisms and autoimmune diseases, several experimental approaches are valuable for investigating its role:

• Genetic association studies: Examining correlations between Clec4a polymorphisms and autoimmune disease incidence or severity in human populations. Research has already shown positive associations with certain autoimmune conditions .

• Animal models of autoimmune disease: Using Clec4a knockout mice or antibody-mediated inhibition in models of diseases like experimental arthritis, autoimmune encephalomyelitis, and other inflammatory conditions. Studies show that Clec4a2 protects from experimental arthritis and autoimmune encephalomyelitis by negatively regulating dendritic cell activation .

• Ex vivo analysis of patient samples: Comparing Clec4a expression and function in immune cells from patients with autoimmune diseases versus healthy controls. This is particularly relevant for rheumatoid arthritis, where Clec4a has been found on CD4+ T cells from patients .

• Functional studies of disease-associated variants: Investigating how disease-associated Clec4a polymorphisms affect protein function, expression, and downstream signaling pathways.

• Therapeutic intervention studies: Testing whether enhancing Clec4a function (opposite to the approach in cancer) might reduce autoimmune pathology in experimental models.

These approaches can help determine whether Clec4a dysfunction contributes to autoimmune disease pathogenesis and identify potential therapeutic strategies.

How can researchers effectively validate Clec4a antibody specificity for their experiments?

Validating Clec4a antibody specificity is crucial for experimental reliability and requires multiple complementary approaches:

• Positive and negative control cell lines: Test antibodies on cell populations known to express Clec4a (e.g., dendritic cells, monocytes) versus those that do not. For human CLEC4A, neutrophils, monocytes, dendritic cells, and B cells serve as positive controls .

• Knockout validation: The gold standard is testing antibodies on knockout models (Clec4a-/- mice) or cells with CRISPR-mediated knockout of Clec4a to confirm absence of signal.

• Competitive binding assays: Pre-incubating with unlabeled antibody or recombinant Clec4a protein should block specific binding of labeled test antibody.

• Western blot analysis: Confirm that the antibody detects a protein of the expected molecular weight.

• Cross-reactivity testing: For studies comparing human and mouse proteins, ensure antibodies do not cross-react between species unless specifically designed to do so.

• Isotype controls: Always use appropriate isotype control antibodies to distinguish specific from non-specific binding, particularly in flow cytometry.

This multi-faceted validation approach ensures that experimental results truly reflect Clec4a biology rather than artifacts of non-specific antibody binding.

What are the challenges in developing specific antibodies against different Clec4a variants?

Developing specific antibodies against different Clec4a variants presents several challenges:

• Sequence homology: Different Clec4a family members share significant homology, making it difficult to develop antibodies that distinguish between variants. This is particularly challenging when studying multiple mouse Clec4a variants (Clec4a2, Clec4a4) simultaneously.

• Species differences: While functional orthologues exist between mouse and human (mClec4A4 and hCLEC4A), structural differences can complicate development of cross-reactive antibodies for translational studies .

• Post-translational modifications: N-glycosylation of Clec4a affects its function and potentially antibody recognition, so expression systems must maintain appropriate modifications .

• Conformational epitopes: The functional conformation of Clec4a may present important epitopes that are lost during antibody development using linearized proteins or peptides.

• Validation requirements: Ensuring specificity requires extensive validation across multiple Clec4a family members and appropriate controls, including knockout models.

Researchers have addressed these challenges by using carefully designed immunogens, such as the ectodomain of CLEC4A-human Fc fusion protein used to develop the PE anti-human CD367 clone 9E8 antibody .